Sutro Biopharma, Inc. · NASDAQ:STRO
Sutro Biopharma — Investor Presentation (November 2020)
28 slides from Sutro Biopharma's investor presentation, November 2020
Slide 1: Company Overview
Company Overview November 2020 NASDAQ: STRO Bill Newell, CEO NON-CONFIDENTIAL
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than state
Slide 3: Investment Highlights
Investment Highlights Sutro’s novel platform delivering on promise to change the future of oncology Potential for best-in-class products Validating partnerships Versatility of the Sutro platform allows for value- STRO STRO driving collaborations with our partners: 002 001 FolRα-Targeting ADC CD74-Ta
Slide 4: Sutro Owned and Partnered Pipeline
Sutro Owned and Partnered Pipeline Programs developed out of proprietary platform Program Discovery Preclinical Phase 1/1b Phase 2/3 Commercial Rights STRO-002 FolRα-Targeting ADC Ovarian and Endometrial Cancer STRO-001 Lymphomas; DLBCL, Mantle Cell, Follicular CD74-Targeting ADC Multiple Myeloma (O
Slide 5: FolRα-Targeting ADC
STRO 002 FolRα-Targeting ADC Potential Best-in-Class ADC for Ovarian and Endometrial Cancers NON-CONFIDENTIAL
Slide 6: STRO-002 Structure and Design
STRO 002 STRO-002 Structure and Design Optimized molecule provides potential for best-in-class • STRO-002 is a novel homogeneous antibody drug conjugate using precisely positioned non-natural amino acids • STRO-002 has a drug-antibody ratio of 4:1, with a proprietary cleavable hemiasterlin linker-wa
Slide 7: Heavily Pretreated Ovarian Cancer Patients: Demographics/Dose Levels
STRO 002 Heavily Pretreated Ovarian Cancer Patients: Demographics/Dose Levels Data as of August 31, 2020 Characteristic Total N = 39 (%) Characteristic Total N = 39 (%) Age, median (range), years 61 (48-79) Dose Level of STRO-002 Tumor type 0.5 mg/kg, 1.0 mg/kg, 1.8 mg/kg 5 (13) EOC 30 (77) Fallopia
Slide 8: STRO-002 is Generally Well Tolerated
STRO 002 STRO-002 is Generally Well Tolerated Safety Profile Is Encouraging • 87% of AEs were Grade 1–2 • No need for prophylactic corticosteroid eyedrops • Neutropenia readily reverses within 1 week, without the need for G-CSF • Peripheral neuropathy/arthralgia can be managed with dose reduction/de
Slide 9: Robust Anti-Tumor Activity in Heavily Pre-Treated, Unselected Patients
Robust Anti-Tumor Activity in Heavily Pre-Treated, STRO 002 Unselected Patients Best % change in sum of target lesions from baseline 50 Evaluable patients treated at ≥ 2.9 mg/kg, N=29 40 +30 30 +19 20 +13 10 +6 +6 +4 +2 +1 ORR: 24% (8/33) 0 -2 -3 -5 -6 -6 -11 -18 -19 -21 -22 -22 -26 -29 -32 -32 -33
Slide 10: Partial Response Achieved in 24% of Unenriched, Heavily Pre-Treated Ovarian Cancer Patients
Partial Response Achieved in 24% of Unenriched, STRO 002 Heavily Pre-Treated Ovarian Cancer Patients 2.9 mg/kg 1st PR - week 6 cPR 6.0 mg/kg 1st PR - week 14 5.2 mg/kg uPR 1st PR - 6.0 mg/kg 4.3 mg/kg (after delay – DLT) week 36 uPR 6.0 mg/kg 5.2 PR - 4.3 week 22 mg/kg uPR mg/kg = Dose reduction 5.2
Slide 11: Partial Response with 74% Tumor Reduction
STRO 002 Partial Response with 74% Tumor Reduction Patient continues on treatment Baseline Confirmed PR after 4 cycles 3/16/20 06/29/20 57-year-old woman with platinum resistant ovarian cancer progressing after 4 prior regimens received STRO-002 at 5.2 mg/kg and remains on study treatment Data as of
Slide 12: Long Duration on Study and Disease Control Observed
Long Duration on Study and Disease Control Observed in STRO 002 Unenriched, Heavily Pre-Treated Ovarian Cancer Patients 2.9 mg/kg cPR 2.9 mg/kg cSD 4.3 mg/kg 4.3 mg/kg cSD cSD ORR: 24% (8/33) 6.0 mg/kg uPR 6.0 mg/kg uPR 5.2 mg/kg cSD 6.0 mg/kg uPR 4.3 mg/kg 5.2 mg/kg cSD cSD DCR at ≥ 12 weeks: 6.0 m
Slide 13: High Rates of CA-125 Responses are Associated with Anti-Tumor Activity
High Rates of CA-125 Responses are Associated with STRO 002 Anti-Tumor Activity Y axis- change from C1D1 CA-125 100% 72% (18/25) of patients with elevated CA-125 levels at baseline had ≥ 50% reduction in CA-125 in at least 1 post-treatment timepoint 50% Change from C1D1 • 10/25 (40%) have confirmed
Slide 14: Improved Efficacy Outcomes Observed as Data Matures with Longer Follow-Up
Improved Efficacy Outcomes (Increased ORR and DCR) STRO 002 Observed as Data Matures with Longer Follow-Up STRO-002 Clinical Data Readout April 20, 2020 Interim Analysis August 31, 2020 Interim Analysis N ≥ 2.9 mg/kg(1) 25 (20 evaluable) 34 (33 evaluable) Median Age 61 (47–76) 61 (48–79) Median Prio
Slide 15: Summary and Next Steps in Clinical Development
STRO 002 Summary and Next Steps in Clinical Development • STRO-002 is clinically efficacious at multiple doses, starting at 2.9 mg/kg • Dose reductions or delays were not associated with loss of anti-tumor activity • Further dose optimization will be explored during dose expansion • Anticipate RP2D
Slide 16: CD74-Targeting ADC
STRO 001 CD74-Targeting ADC Potential First and Best-in-Class ADC for B-Cell Malignancies NON-CONFIDENTIAL
Slide 17: STRO-001 Structure and Design
STRO 001 STRO-001 Structure and Design First-in-class molecule with potential for improved patient outcomes • STRO-001 is a novel homogeneous antibody-drug conjugate using precisely positioned non-natural amino acids • STRO-001 comprises two non-cleavable maytansinoid linker-warheads (DAR=2) that ar
Slide 18: Interim Update on NHL Cohort Dose-Escalation at ASH
STRO 001 Interim Update on NHL Cohort Dose-Escalation at ASH Abstract published on Nov 4th and ASH presentation on Dec 7th 3030 Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma
Slide 19: Delivering On Our Collaborations
Delivering On Our Collaborations BCMA-targeting ADC (CC-99712): IND Anticipated in 2H2021: • Phase 1b/2 trial for multiple myeloma (dose escalation • Formerly SutroVax – spinout using XpressCF+™ began 2H 2019) • Potential best-in-class pneumococcal conjugate and other • ~$236M total funding received
Slide 20: CC-99712 (BCMA-Targeting ADC)
CC–99712 (BCMA-Targeting ADC) Potential for best-in-class – Phase 1B/2 Study CC-99712 Molecule Ongoing Study of Dose Escalation (Q3W) Site-specific conjugation leads to Drug-antibody Ratio (DAR) = 4 DL7 10.0 mg/kg DL6 6.7 mg/kg N=3-6 DL5 4.5 mg/kg N=4 DL4 3.0 mg/kg O O O O O O O N = 2 DL3 2.0 mg/kg
Slide 21: M1231 (MUC1-EGFR Bispecific ADC)
M1231 (MUC1-EGFR Bispecific ADC) Potential for first-in-class – 1Q21 First In Human Planned • First bispecific ADC to go to clinic; M1231 targets MUC1 & EGFR EGFR • Combines next generation technologies; stable site-specific XpressCF+™ conjugation, optimized positioning of a MUC1 proprietary hemiast
Slide 22: M1231: Strong efficacy in preclinical NSCLC & esophageal cancer PDX models
M1231 (MUC1-EGFR Bispecific ADC) Strong efficacy in preclinical NSCLC & esophageal cancer PDX models • A single M1231 application was associated with complete remission in a subset of preclinical NSCLS and sqCC esophageal PDX models • Tumor response seems to be associated with target expression Sour
Slide 23: Sutro's Research Discovery Efforts
iADC Sutro’s Research Discovery Efforts Next Generation Tumor Targeting Immunostimulatory ADC iADC: Off the shelf, systemically administered in situ immunization • Breakthrough technology for dual conjugated immunostimulatory antibody drug conjugate • Designed and enabled using Sutro’s XpressCF+TM p
Slide 24: Immunostimulatory ADC Provides Enhanced Immune Cell Activation and Anti-Tumor Immunity
Immunostimulatory ADC Provides Enhanced iADC Immune Cell Activation and Anti-Tumor Immunity MC38-hFolR mouse model iADC single dose causes iADC treated mice resistant to some complete responses future re-challenge Control (iADC) ISAC (TLR agonist alone) ADC (Cytotoxin alone) iADC (Cytotoxin + TLR ag
Slide 25: Financial Overview
Financial Overview Well-capitalized through cash and other financial sources As of Sept 30, 2020 Projected cash runway into Cash, cash equivalents and marketable securities of 2H 2022, $202.4M not including potential monetization of Vaxcyte shares or future BD ~1.6M shares of Vaxcyte (Nasdaq: Fundin
Slide 26: Executed and Anticipated Value Drivers
Executed and Anticipated Value Drivers Multiple opportunities to impact value into 2021 and beyond ✓ Update on iADC preclinical development (2Q 2020) ✓ Initial STRO-002 data update at AACR (2Q 2020) ✓ Interim STRO-002 data update at IGCS (3Q 2020) 4Q 2020: Commence dose-expansion portion of Phase 1
Slide 27: Experienced Leadership Team
Experienced Leadership Team Trevor Hallam, PhD Arturo Molina, Ed Albini Chief Scientific Officer MD, MS, FACP Chief Financial Officer Chief Medical Officer William Newell, JD Chief Executive Officer and Member of the Board of Directors Shabbir Anik, PhD Linda Fitzpatrick Nicki Vasquez, PhD Chief Tec
Slide 28: Company Overview
Company Overview November 2020 NASDAQ: STRO Bill Newell, CEO NON-CONFIDENTIAL
Sutro Biopharma — Investor Presentation (November 2020) on 6ix